AnaptysBio, Inc.
ANAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | -0.88 | -0.05 | 0.14 |
| FCF Yield | -3.08% | -6.30% | -1.88% | -16.60% |
| EV / EBITDA | 29.46 | -33.20 | -23.60 | -77.80 |
| Quality | ||||
| ROIC | 10.95% | -8.67% | -7.25% | -2.20% |
| Gross Margin | 58.85% | -69.90% | -48.28% | 1.22% |
| Cash Conversion Ratio | -1.81 | 1.04 | 0.27 | 3.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 124.59% | 111.95% | 118.73% | 107.03% |
| Free Cash Flow Growth | 32.06% | -275.25% | 83.96% | -561.09% |
| Safety | ||||
| Net Debt / EBITDA | 6.19 | 1.59 | 4.03 | 28.12 |
| Interest Coverage | 1.54 | -1.33 | -1.52 | -0.56 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 80.96 | 78.66 | 44.58 | 76.64 |